Signal Transduction and Targeted Therapy · 2024 · 45 citations · 17 references
PharmacyBiotechnologyOncologyDrug DeliveryMolecular OncologyTargeted Drug DeliveryCancer BiotechnologyOligonucleotide DeliveryTargeted Cancer TherapyAptamer - Target Binding AffinityAptamer-based TargetingCellular ChemotaxisClick Chemistry FunctionalizationDelivery Vehicle DevelopmentNucleic Acid EncapsulationNucleic Acid ProbesSerum Stability Enhancement
Pancreatic cancer is one of the most malignant tumors with the highest mortality rates, and it currently lacks effective drugs. Aptamer-drug conjugates (ApDC), as a form of nucleic acid drug, show great potential in cancer therapy. However, the instability of nucleic acid-based drugs in vivo and the avascularity of pancreatic cancer with dense stroma have limited their application. Fortunately, VNP20009, a genetically modified strain of Salmonella typhimurium, which has a preference for anaerobic environments, but is toxic and lacks specificity, can potentially serve as a delivery vehicle for ApDC. Here, we propose a synergistic therapy approach that combines the penetrative capability of bacteria with the targeting and toxic effects of ApDC by conjugating ApDC to VNP20009 through straightforward, one-step click chemistry. With this strategy, bacteria specifically target pancreatic cancer through anaerobic chemotaxis and subsequently adhere to tumor cells driven by the aptamer's specific binding. Results indicate that this method prolongs the serum stability of ApDC up to 48 h and resulted in increased drug concentration at tumor sites compared to the free drugs group. Moreover, the aptamer's targeted binding to cancer cells tripled bacterial colonization at the tumor site, leading to increased death of tumor cells and T cell infiltration. Notably, by integrating chemotherapy and immunotherapy, the effectiveness of the treatment is significantly enhanced, showing consistent results across various animal models. Overall, this strategy takes advantage of bacteria and ApDC and thus presents an effective synergistic strategy for pancreatic cancer treatment.
17
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations
Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy
Wenfei Chen, Ying Wang, Ming Qin et al. · ACS Nano · 2018 · 382 citations
Medicine, Cancer Biology, Oncology +17
Aptamer-assisted tumor localization of bacteria for enhanced biotherapy
Zhongmin Geng, Zhenping Cao, Rui Liu et al. · Nature Communications · 2021 · 173 citations · Full text
Medicine, Oncology, Pharmaceutics +12
Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma
Oliver Strobel, P. Lorenz, Ulf Hinz et al. · Annals of Surgery · 2020 · 142 citations